MedPath
NMPA Approval

Galcanezumab Injection

国药准字SJ20240003

January 5, 2024

Drug Information

加卡奈珠单抗注射液

恩加乐

注射剂

预充式注射笔:120 mg(1 mL)/ 支

生物制品

January 5, 2024

January 4, 2029

Company Information

Applicant Company

Papendorpseweg 83, 3528BJ Utrecht, The Netherlands

Manufacturing Company

Lilly Corporate Center, Indianapolis, Indiana (IN) 46285, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

加卡奈珠单抗注射液 - NMPA 批准文号 | MedPath